Nektar Therapeutics NKTR Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Cash.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's cash & equivalents?
- Nektar Therapeutics (NKTR) reported cash & equivalents of $5.7M in Q1 2026.
- How has Nektar Therapeutics's cash & equivalents changed year-over-year?
- Nektar Therapeutics's cash & equivalents decreased by 20.0% year-over-year, from $7.12M to $5.7M.
- What is the long-term trend for Nektar Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Nektar Therapeutics's cash & equivalents has grown at a -12.7% compound annual growth rate (CAGR), from $6.29M to $3.2M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.